Product Images Andexxa

This is a chart showing the Anti-fXa levels (measured in ng/mL) at the end of bolus and end of infusion for a group of 8 patients who received a placebo bolus and 2-hour infusion, and a group of 23 patients who received an Andexxa 400mg bolus and 480mg 2-hour infusion. The chart also shows the time after bolus in hours.*

This is a graph showing the results of administering a placebo bolus and 2-hour infusion on 13 people compared to administering ANDEXXA (a medication used to reverse the effects of anticoagulants) in an 800 mg bolus and 860 mg/2hr infusion on 26 people. The graph measures the levels of Anti-Xa (ng/mL) at the end of the bolus and the end of the infusion, with time after the bolus (hr) marked on the x-axis.*

ANDEXXA is a medication containing recombinant coagulation factor Xa, inactivated-zhzo, intended for intravenous use only. It is available in the form of lyophilized powder to be dissolved in sterile water for injection. Each vial contains 200mg coagulation factor Xa (recombinant), inactivated-zhzo, 1g of maltose, 7.3mg of sodium citrate, 948mg of L-arginine hydrochloride, 200mg of sucrose, 500mg of mannitol and 2mg of polysorbate 80. The medication is sold in a package with four 200 mg single-dose vials and should be stored refrigerated at 2°C to 8°C (36°F to 46°F). For dosage and administration, a package insert is included. The manufacturer of ANDEXXA is Alexion Pharmaceuticals, Inc., and it is a product of Spain.*